deltatrials
Completed PHASE3 NCT00065637

Once Weekly Parathyroid Hormone for Osteoporosis

PTH Once Weekly Research (POWR)

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Conditions Osteopenia Osteoporosis
Interventions Placebo teriparatide Teriparatide
Updated 5 times since 2017 Last updated: Feb 4, 2013 Started: Dec 31, 2003 Primary completion: Sep 30, 2005 Completion: Sep 30, 2005

This PHASE3 trial investigates Osteopenia and Osteoporosis and is currently completed. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) leads this study, which shows 5 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  • University of California, San Francisco
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bangor, United States